Target intelligence / Profile preview

HOXC13 antisense RNA (HOXC13-AS)

Target: HOXC13-AS
Molecular classification: Long non-coding RNA (lncRNA), Antisense RNA, Non-protein coding RNA, Homeobox cluster-associated RNA

Overview

HOXC13 antisense RNA (HOXC13-AS) is a long non-coding RNA (lncRNA) transcribed from the reverse strand of chromosome 12 at position 12q13.13. It spans three exons and overlaps with the HOXC13 gene. This lncRNA exhibits abnormal expression in several cancers, including nasopharyngeal carcinoma, breast cancer, oral squamous cell carcinoma, glioma, and cervical cancer. HOXC13-AS modulates tumor biology by acting as a competing endogenous RNA (ceRNA), sponging specific microRNAs and thereby regulating key oncogenes and tumor suppressors linked to cell proliferation, migration, invasion, and EMT. Its expression is closely associated with clinical outcomes, making it a promising diagnostic and prognostic cancer biomarker and a novel target for potential therapeutic intervention.

Other names: HOXC-AS5HOXC cluster antisense RNA 5 (non-protein coding)HOXC13-AS

Mechanism of action

Competitive binding to microRNAs (ceRNA mechanism). Regulation of downstream oncogenes and tumor suppressors via miRNA axis (e.g., HOXC13-AS/miR-383-3p/HMGA2, HOXC13-AS/miR-378g/HOXC13, HOXC13-AS/miR-122-5p/SATB1/c-Myc loop).

Biological functions

Cell proliferationCell migrationCell invasionEpithelial–mesenchymal transition (EMT)Tumor growthCompeting endogenous RNA (ceRNA) function (miRNA sponge)

Disease associations

CancerTumor progressionNasopharyngeal carcinomaBreast cancerOral squamous cell carcinomaGliomaCervical cancer

Safety considerations

None specifically reported for targeting HOXC13-AS, but therapeutic targeting of lncRNAs may be limited by delivery challenges, off-target effects, and incomplete safety profiles in clinical settings

Interacting drugs

None currently listed; lncRNAs like HOXC13-AS are potential drug targets, but no approved drugs or clinical candidates directly target this molecule yet

Biomarkers

HOXC13-AS expression level (predictive biomarker for diagnosis, prognosis, and disease staging in cancer)

Beyond the preview

Go deeper on HOXC13 antisense RNA (HOXC13-AS).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HOXC13 antisense RNA (HOXC13-AS).

Explore the full profile